Aim: Clinical interpretation of B-Type Natriuretic Peptide (BNP) levels in hemodialysis patients (HD) for fluid management remains elusive.
INTRODUCTION
Biomarkers such as Natriuretic peptides (BNP, NT-proBNP) have been established as markers of mortality and cardiac events in Coronary Artery Disease (CAD) and Heart Failure (HF). 1 Both markers have been correlated with several cardiac parameters (Blood Pressure=BP, Left Ventricular Hypertrophy= LVH or LV systolic function) and non-cardiac parameters (Age, Gender, Diabetes mellitus or Body Mass Index=BMI). 2, 3 Furthermore, some authors have also emphasized the utility of "BNP-targeted" heart-failure therapy in clinical practice. 4, 5 In end stage renal disease (ESRD), especially in hemodialysis patients (HD), Cardiovascular Disease (CVD) is a burden and remains the first cause of mortality. 6 If both BNP an NT-Pro BNP are markers of cardiac events in ESRD, their use and interpretation (HD) still remains challenging. BNP levels are often increased in HD. This can be partially explained by a decreased renal elimination but mainly by multiple factors both intrinsic (variability in measurement, type of BNP) and extrinsic related to patient comorbidity, including CVD or malnutrition. 7, 8 . There is considerable variation in BNP levels over time and the cut-off values to define disease are not standardized across heterogeneous groups of patient populations. [9] [10] [11] [12] [13] [14] Finally, the potential role BNP as a biomarker for fluid overload (FO) has been disappointing with discrepant results in small studies. [9] [10] [11] [12] There is still debate as to whether this cardiac biomarker is more reflective of FO or intrinsic cardiac dysfunction in HD. Taken together, previous studies in HD have revealed that BNP levels can be influenced by many factors that may not have the same impact on BNP levels, and anticipation of a certain "targeted BNP level" to guide fluidremoval therapy is still missing. When considering the interaction of different parameters for a specific outcome, mathematical modelling can be used as a robust method to understand and predict biological response. It has been widely used in pharmacodynamics to predict a drugs response, or in biology to predict cellular response. 13 We attempted to model the BNP level depending on several clinical and biological parameters in order to predict the "targeted" BNP for a given patient.
The aim of the study was to; (1) assess to which extent each parameter will contribute to the BNP variation, and (2) to define a "targeted BNP" that could be used as a marker of fluid overload and to guide ultrafiltration. We built a mathematical model based on 6 clinical and biological variables that could be easily obtained at the patient bedside. We show for the first time the complex contribution of each variable in the modulation of BNP levels and the limitation in its interpretation such as age, CD and Dry Weight.
MATERIALS AND METHODS
The present study aimed to build a mathematical model, which enables accurate investigation of the relationship between BNP and clinical and biological parameters.
Patient population:
We initiated a single centre, observational, retrospective study of adult (>18 years old) HD. In our centre, BNP measure is performed monthly with the routine blood test, since 2014.
BNP level was performed before dialysis at the midweek session. Midweek measure was used to standardize results as it leads to a relative constant level of BNP. 14 
Estimation of Dry Weight and Fluid Overload
We used two different approaches to estimate the FO: (1) a "clinician approach" based on the dry weight (DW) estimated by the clinician. The clinician FO was defined by c-FO = predialysis weight -DW; (2) a "bio-impedancemetry approach" that estimates the NHW. The bio-impedancemetry FO was defined by the FO = the predialysis weight -NHW. These 2 approaches were implemented into the models construction. The NWH was determined by BCM according to the manufacture's instructions (Fresenius). Bio impedance analysis is a reliable, repetitive, and simple, technique to assess the fluid status of a dialysis patient. 15, 16 Modelling BNP level.
We performed a longitudinal study of all biological and clinical parameters measured monthly during 6 months. The asymmetrical distribution of BNP led us to consider a logtransformation for the statistical analyses, assuming a normal distribution for the log-BNP.
We first identified clinical and biological variables that have been shown to be associated A test for interaction was performed for all variables. Benjamini-Hochberg procedure to was used properly take into account the multiple comparisons 
Statistical analysis of demographic or biological characteristics.
All data with normal distribution were reported as a mean ± SD or a percentage. Comparisons between patients were performed using a non-parametric test (Whitney test) or chi-square test, and Fisher's exact test, as appropriate. Statistical significance was first established for a p value < 0.05.
RESULTS

Baseline Characteristic of the 2 data set.
Demographic and biological characteristics of cohort 1 and cohort 2 at the beginning of the study (=M0) are shown in Table 1 . For cohort 1, the mean age was 67.1 years (range 21-93). 
Construction and selection of a predictive model
We generated nine models that included the 15 clinical and biological variables (see materials and methods). We then selected among all the possible linear models the one that shows the best predictive performance for the BNP level, according to the Bayesian Information Criteria (BIC) (nine of the models are reported in supplemental Table S1 ).
Briefly, the model with the lowest BIC is preferred. The best model obtained (=model m2) includes the following variables: Age, sBP, CD, Albumin, NHW and FO. The complete equation is detailed in the materiels and methods section. It should be noted that the model including FO estimated by bio-impedancemetry was considered slightly better than the one based on a "clinician-approach" for predicting the BNP level. Furthermore, diabetes mellitus, BMI and antihypertensive drugs that have been reported to influence BNP levels were not included from the final model. 
Optimisation of the model
The correlation between the measured log-BNP and the predicted log-BNP was 0.567 in the learning set and was similar to the validation set (r=0.543). However, the multiple R-square, which determines the proportion of variability explained by the model, was low 0.32. This indicates that the 6 variables only explain 1/3 of the log-BNP variability (multiple R-square = 0.32)
To improve the robustness of our model, we added the baseline values for the six variables at M0 as an additional explanatory variable in order to predict the BNP at further time points (M+1). The correlation between the measured log-BNP and the predicted log-BNP then increased to 0.794 (multiple R-square = 0.63) for the learning set and 0.759 for the validation set ( Figure 1 ). It should be note that Age, CD and to a lesser extent NHY won't change between Mx and Mx+1. Thus the addition of BNP and sBP mainly explained the better correlation observed. These results emphasised the fact that a longitudinal screening of the BNP is mandatory.
Assessing the contribution of each variable.
Our model allows us to specifically assess the contribution of each variable for the BNP prediction, and to which extent they modulated BNP levels (Figure 2-4) ;. We defined a standard hemodialysis patient, 67 years old, sBP 130/80 mmHg, FO=0, Albumin =36.5 g/l.
By fixing values for 5 out of 6 variables, we could easily assess the effect of the remaining variable on the BNP level. For example, Figure 1 represents the predicted BNP according to age when sBP =130/80 mmH, FO=0 kg and albumin=36.5 g/l respectively.
We observed 3 different kinds of BNP modulation (1) Effect of age and sBP mimic a dose-response curve (Sigmoid Curve) suggesting a minimal and maximal. Our model reveals BNP levels increase with age from 30 to 60 years old from 95 to 249 ng/ml (Fold Change FC = 2.83), before reaching a plateau (Fig 2A) . From 60 to 80 years, BNP levels only increase from 249 to 268 ng/ml. A similar effect was observed for the sBP (Fig 2B) . For a sBP< 150 mmHg, we observed a small variation of BNP level from 251 to 287 ng/ml. However, BNP increases from 287 to 487 ng/ml if sBP rises to 200 mmHg (FC = 1.69). The effect observed here was independent of the FO.
(2) A negative "linear effect" for albumin and NHW (Figure 3) . For Each 10 g/l of albumin, BNP decrease with a FC=1.4 (Figure 3A) . We observed that BNP levels also decrease with the NHW. The predicted BNP was 360, 260 and 188 ng/ml for a NHW of 45, 70 and 100kg respectively without CD (Figure 3B) . Define the "right" BNP for a given patient.
Our model allows us to establish the "right" BNP is for a given patient. It could help clinician to target it for dry weight adjustment ( Table 3 and TableS3) resume values of predicted-BNP and the 95% IC according to different values for Age, Weight, FO and CD. We intentionally fixed values for Albumin and sBP to avoid too much information.
DISCUSSION
B-Type Natriuretic peptides have emerged as a useful biomarker in HF or CAD. In HD, BNP may be used as a sensitive marker of mortality but only in stable patients without HF, LVD or complex comorbidities. [19] [20] [21] However, interpretation of BNP levels is more complex due to the specific pathophysiology of ESRD and the presence of multiple comorbidities. All these confounding factors explain partially why studies fail to demonstrate the clinical use of BNP as a marker of fluid overload or to guide fluid removal. Anticipation of BNP values for a patient according to their clinical characteristics is lacking. In the present study, we built a mathematical model to predict the BNP in hemodialysis according to clinical and biological variables.
In our model, we identified the three variables that contribute the most significantly to BNP levels in dialysis patients: age, CD and FO. All these variables have been already associated with BNP level, but to which extent they contribute to it variation is new. It is known that age is correlated with BNP levels in HF, CAD and dialysis. In our study population. For example, BNP increases with age in a linear manner up to 60 years. After this threshold, age does not influence BNP levels, suggesting that older patients will have similar baseline BNP levels. A similar effect was observed with sBP suggesting that the stretch of Left Ventricle induced by low sBP have minor effects on BNP modulation. However, it should be noted that the relation between blood pressure and BNP might be confounded by the use of medications (e.g RAAS or beta-blockers). 22 Malnutrition has been associated with BNP levels in HD based on BCM markers but not biomarkers such as albumin. 8 Here we emphasized the tight relationship between albumin and BNP. Albumin is not the optimal marker of malnutrition but its level is associated with poor outcome in HD. 23 Our model also shows that BNP levels decrease according to a patients' weight, similarly to These results correspond to what has been described with BMI and BNP levels, where lower circulating levels are observed in patients with a higher BMI [24] [25] [26] [27] . One possible explanation is that BNP clearance is increased due to the presence of the natriuretic peptide Clearance receptor (NPR-C) in adipose tissue.
However, cardiac cachexia might also explain the higher BNP values in cases of low weight.
This finding raises concern about the interpretation, predictive values and choice of cut-off values for Natriuretic peptides as in HF or reduced LVF. 24, 26 Our model emphasized that BNP levels are influenced by both intrinsic cardiac pathology HD and FO volume. In our 2 cohorts, even without HF, patients with a history of CAD or an AF had higher BNP levels compared to other HDs, independently of age or FO. This finding could reflect the presence of LVH observed in our patient. However, as HF measures (LVH, LVD) were excluded from the model, we could not definitively conclusion whether BNP is more reflective of FO or intrinsic cardiac dysfunction.
The potential role of BNP as a biomarker of volume excess is controversial [9] [10] [11] [12] as compare to NT-Pro-BNP (60-120 min), which will result in a higher variability of measure.
We used a third generation kit for BNP measure that was different for previous reports. 8, 9, 11 Even if the performance of all Third generation kit showed similar result in HF or CAD with mild CKD (Stage 3-4) , it is not known if their predictive values can be extrapolated to HD patient.
Secondly, the lack of inclusion of measure of LVH or LVD that are correlated well with BNP measure is also a major limitation. We also focused on clinical and biological variables that could be easily retrieve at bedside, which introduced bias. Finally, we acknowledged that the robustness of our model may be limited by it intrinsic properties. Several mathematical models (multiple linear regression, Polynomal regression or artificial network...) may be considered to predict a specific outcome. Each of them has their own advantage or limits.
Our study has however several limitations. First, it is retrospective mono-centre study without external validation. As mentioned earlier, variability in BNP measure and lack of echocardiographic measures weaken our results. The latter were excluded for 2 main reasons:
1/ data were not available for all patients at the beginning of the observational study and 2/ Echocardiography were also performed during the 6 months observational study at various time point by at least 5 different operators. The latter could also give rise to residual cofounding in our model.
Finally we did not perform quantification of diuresis in our patients because of the retrospective analysis, and the absence of consensus for diuresis estimation in hemodialysis.
Notwithstanding, our study has however several strengths including, the number of patients 
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Figure 1
Correlation between predicted BNP and measured BNP for the learning set (A), and the validation set (B).
Figure 2
Predicted Benjamini-Hochberg multiple comparison test was used for the p-value adjusted. 
